在 #ESMO26 见到来自 @NEUniversitesi 的 Ugrakli 医生和 Artac 医生，真是一个美好的时刻。Ugrakli 医生提到，在看到 @NazliDizman 介绍她与 #CBM588 相关的研究后，她以之为范本，设计了自己的 nivolumab +/- BL-04（一种 Bifidobacterium animalis 菌株）研究。仔细看看吧——早期 OS 信号很有意思。海报交流环节中有许多隐藏的瑰宝；一定要来参加！@OncoAlert @DrYukselUrun @yekeduz_emre @ziremozay
78 浏览 · 6 赞 · 1 转发 · 0 回复
Emotional distress (ED) upfront neoadjuvant ipilimumab + nivolumab (IPI+NIVO) is associated with lower pathological response and toxicity
https://esmocongress.esmo.orgPost-surgical molecular residual disease and pathological complete response after perioperative nivolumab in resectable stage III NSCLC: Exploratory analysis from NADIM II
https://esmocongress.esmo.orgResults from a phase 3 trial of neoadjuvant (neoadj) chemotherapy alone vs in combination with nivolumab followed by postsurgical adjuvant nivolumab in patients (pts) with muscle-invasive bladder cancer (MIBC)
https://esmocongress.esmo.orgFinal pathological and radiological outcomes and initial EFS from a blinded, exploratory phase 2 trial of nivolumab ± visugromab in MIBC (GDFather-NEO)
https://esmocongress.esmo.orgPrimary analysis of HBI-8000-303: A randomized phase 3 trial of nivolumab plus HBI-8000 or placebo in advanced melanoma
https://esmocongress.esmo.org- **标题 / Title：** Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)
https://esmocongress.esmo.org来源：Sumanta K. Pal, MD, FASCO · x.com